Kisunla: New FDA-Approved Alzheimer's Drug Explained

episode

Speaking of Alzheimer's not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Speaking of Alzheimer's

Becoming a Caregiver Overnight: A Daughter’s Viral Story 25 min · 13 Aug 2026

AAIC 2026: Breaking Down the Top Alzheimer's Research Announcements 23 min · 17 Jul 2026

The Healing Power of Music & Alzheimer's 22 min · 18 Jun 2026

All episodes from Speaking of Alzheimer's →

Report any issue

Source

Recorded10 Jul 2024

Publisheranchor.fm ↗

Handlerec:1533726

Show notes

On this special episode we’re discussing the new FDA-approved drug Kisunla (donanemab) for the treatment of people living with early symptomatic Alzheimer’s disease. We’re joined by Dr. Margarita Reyes, a physician at Bristol Health Group in Connecticut, who explains how Kisunla works, the difference between Kisunla and Leqembi, side effects, and much more. Need assistance? Call the Alzheimer’s Association 24/7 Helpline (800.272.3900).

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.